Filing Flows › Steris (STE) › Q4 FY25
Steris (STE) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed May 29, 2025
Steris (STE) reported revenue of $1.5B for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and +8% from the quarter before. Operating margin was 14.6%, net earnings $146M (9.9% of revenue).
Steris, Q4 FY25: revenue $1.5B (+4% year over year), operating margin 14.6%, net earnings $146M, operating cash flow $261M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5B | +8% | +4% |
| Gross profit | $641M | +5% | +10% |
| Operating profit | $216M | -12% | -2% |
| Net earnings | $146M | -16% | — |
| Operating cash flow | $261M | -22% | +2% |
| Free cash flow | $190M | -22% | +16% |
What changed
Revenue was $1.5B in Q4 FY25, up 4% year over year and up 8% from the previous quarter. Product was the largest line at 54% of revenue.
Gross margin was 43.3%, up 2.2 points from a year earlier. Operating profit was $0.22B, a 14.6% margin (down 0.9 points year over year). Operating profit fell $4.2M even though revenue rose $0.06B versus a year earlier, so costs grew faster than sales. Operating expenses grew 17% against revenue growth of 4%. The fastest-growing cost line was Other operating costs (+144%). Net earnings were $0.15B. The effective tax rate was 25.7%.
Operating cash flow was $0.26B (up 2% year over year), 179% of net earnings. Non-cash charges added back $0.12B of depreciation and amortization and $0.01B of share-based compensation. Working capital and other items used $0.02B. Capital expenditures of $0.07B left free cash flow of $0.19B.
Questions
What was Steris' revenue in the fourth quarter fiscal 2025?
Steris (STE) reported revenue of $1.5B for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and +8% from the quarter before.
Was Steris profitable in the fourth quarter fiscal 2025?
Operating profit was $216M (14.6% of revenue) and net earnings $146M.
Source: Steris 10-K on SEC EDGAR.